Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Kolumbiens nächster Kupferriese? Warum Investoren dieses 14.000-Meter-Bohrprogramm beobachten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
347 Leser
Artikel bewerten:
(1)

The QbD Group appoints new COO and Senior Director Integration to further align the Group's international activities and acquisition integration processes

Finanznachrichten News

ANTWERP, Belgium, Aug. 18, 2022 /PRNewswire/ -- The QbD Group, formerly known as Quality by Design (QbD), a privately held company with worldwide operations, offering quality solutions to companies in the life science industry, today announced the appointment of Bart Crommelinck as COO and Jurgen Verstraete as Director Integration. The recent rebranding to QbD Group reflects QBD's ongoing transformation into a multinational company employing over 450 highly qualified professionals, with a strong growth and expansion to new services and markets. The Group now serves a broad spectrum of the life science industry, with a focus on ATMPs, medical devices, IVDs, and digital health. The appointment of Bart and Jurgen will help align business and integration processes of newly acquired and to acquire companies worldwide.

QbD Group's new COO, Bart Crommelinkck, left, and new Senior Director Integration, Jurgen Verstraete, right

Bart Crommelinck was COO of AXI, an all-round IT partner in Belgium and the Netherlands with a focus on the Retail, Healthcare, Finance, Service and Industry sectors with various solutions and services. Bart brings 20 years of experience in different start-ups, SME's as well as in banks and telecommunications companies.

Jurgen Verstraete is a senior-operations executive with international focus within Tech/SAAS companies. In the past, Jurgen worked at Ogone (now Worldline), a Belgian payments services provider where he gained experience in mergers, acquisitions and integrations. He was also active at MindSource, a tech company in the heart of Silicon Valley (California), focused on consultancy and provision of top-tier talent in the areas of mobile & front-end development and quality assurance for Silicon Valley's top employers.

Bart Van Acker, founder and CEO of QbD, said:

"This is an exciting time for the QBD Group as we are still growing our already broad ecosystem through strategic alliances and acquisitions to offer an increasingly wide range of skills and expertise from individual brands that have become successful in their own right. We call that our QbDream growth story. This growth however needs a firm alignment of our international business processes and the integration of newly acquired companies, enriching our high-quality portfolio of services. Both Bart and Jurgen bring a wealth of experience in those fields to QbD Group. They will ensure a smooth communication between our different divisions, as well as a swift final phase of acquisition and post-acquisition processes."

About the QbD Group:

Since 2011, QbD has been providing quality solutions for product development and manufacturing. The QbD Group's team offers the skills and expertise for solving complex problems for companies active in the life sciences. The QbD Group is headquartered in Belgium and has over 450 consultants worldwide in the Netherlands, Spain, France, UK, Switzerland, Mexico, Colombia, and the US.

QbD Group offers potential clients a range of services within seven new divisions:

  • Regulatory Affairs: We help our clients in their journey throughout the entire drug and medical device regulatory lifecycle.
  • Clinical: We are an expert clinical solutions provider specialized in medical devices and biotech, offering global CRO services and consultancy.
  • Qualification and Validation: We guarantee that products meet quality demands and comply with regulations through the qualification and validation of your equipment, facilities, and process support.
  • Quality Assurance: We offer the full range of QA services necessary to get your product to market in a safe and compliant way, including auditing from certified auditors, setting up your QMS, and all QP (Qualified Person) activities.
  • Quality Control: Our QC division consists of a GMP laboratory that offers analytical services for testing pharmaceutical raw materials, excipients, and release testing of finished products.
  • Software solutions & services: Our solutions include a cloud-based and pre-validated QMS built for the life sciences, as well as eIFU services which enable IVD and MD manufacturers to digitalize paper Instructions For Use. Our range of services include Computer System Validation and Digital Health services.
  • Go-to-market: We help you launch your product to market by providing marketing and communication services, business development support and sales strategy.

To learn more, visit www.qbdgroup.com.

Media contact:
Peter Goossens
Marketing manager, QbD Group
T: +32 474 43 32 11
pr@qbd.eu

Photo: https://mma.prnewswire.com/media/1880874/QbD_Group_COO_Senior_Director.jpg
Logo: https://mma.prnewswire.com/media/1880875/QbD_Group_Belgium_Logo.jpg

QbD_Group_Belgium_Logo
© 2022 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.